Current Opinion in Rheumatology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of Rheumatology is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editor in Chief and Section Editors for this issue.
EDITOR IN CHIEF
Steven B. Abramson
Steven B. Abramson, MD, is Senior Vice President and Vice Dean for education, faculty and academic affairs at NYU Langone Medical Center, USA. He is the Frederick H. King Professor and Chair of the Department of Medicine. As Vice Dean, he oversees the implementation of the medical school's nationally recognized curriculum for the 21st Century, including the country's first multispeciality three-year pathway to the MD degree.
A graduate of Dartmouth College, Dr Abramson earned his MD from Harvard Medical School and trained at NYU Medical Center and Bellevue Hospital, USA. He served as the Director of the Division of Rheumatology from 2000–2013, and has had numerous leadership positions in academic medicine. He has served on the Board of the National Arthritis Foundation, as Co-Editor of Arthritis & Rheumatism, a member of the Rheumatology Board of the American Board of Internal Medicine (ABIM), President of the Osteoarthritis Research Society International (OARSI), and former chairman of the Arthritis Advisory Committee of the Food and Drug Administration (FDA).
Dr Abramson has extensive experience in both basic science and clinical research in the field of inflammation and arthritis, and has published more than 300 papers on these and related topics. He received the prestigious American College of Rheumatology Distinguished Basic Investigator Award in 2011.
Hasan Yazici is a retired Professor of Medicine and Rheumatology. He currently practices rheumatology, part time, at the Academic Hospital in Istanbul, Turkey. He still attends the weekly dedicated Behçet's syndrome outpatient clinic he started with a group of his colleagues 40 years ago, and co-edits a journal on controversy in Rheumatology, Letter to Editor/Clinical and Experimental Rheumatology.
After he received his MD from the University of Istanbul in 1969, he trained in internal medicine and rheumatology at University of Nebraska and Creighton University (Metabolic Research Unit) in Omaha, Nebraska, USA, where his mentor was Paul D. Saville. After returning to Turkey in 1974 he joined Cerrahpasa Medical Faculty of the University of Istanbul where he started both the multidisciplinary Behçet Disease Outpatient Clinic and the Division of Rheumatology, which he chaired until his retirement 5 years ago. His main research interests are Behçet's syndrome, clinical research methodology, and ethics. He has published many original articles in peer reviewed journals in addition to his text book contributions, editorials, and reviews. Being the most cited author on Behçet's disease on Web of Science, he has recieved a number of prestigious awards and has a long list of memberships in scientific societies which includes being a member of the Science Academy (Turkey), European Academy of Sciences, Master of the American College of Rheumatology and the recipient of the 2012 EULAR award for Meritorious Service in Rheumatology.
Yusuf Yazici, MD, is a Clinical Associate Professor of Medicine at the New York University School of Medicine, USA. Dr Yazici is also the Director of the Seligman Center for Advanced Therapeutics at the NYU Hospital for Joint Diseases, and Director of the Behcet's Syndrome Evaluation, Treatment and Research Center at NYU Hospital for Joint Diseases.
Dr Yazici earned his medical degree from Cerrahpasa Medical Faculty, University of Istanbul, Turkey. He completed his internship and residency at Creighton University in Nebraska, USA, and his fellowship in rheumatology at the Hospital for Special Surgery of Weill Medical College of Cornell University, USA.
His areas of interest are rheumatoid arthritis, early arthritis, patient reported outcomes, database and registry management and monitoring of arthritis patients in regard to clinical response and adverse events related to treatment and Behcet's syndrome. He has published over 200 articles and presented at various national and international meetings over 100 times.
He divides his time between seeing patients and running the Seligman Center, conducting both industry and investigator initiated trials in the areas of RA and Behcet's syndrome.
Jose U. Scher
Dr Jose U. Scher is Assistant Professor of Medicine at the New York University School of Medicine; Director of the NYU-HJD Arthritis Clinic and Director of the NYU Psoriatic Arthritis Center, USA.
Dr Scher was born and raised in Buenos Aires, Argentina, where he received his medical degree and training in clinical immunology at the National Genetic Databank under the mentorship of Ana Di Lonardo. He moved to New York in the early 2000's and graduated from an internal medicine residency and rheumatology fellowship at New York University School of Medicine. After joining the laboratory of Dan Littman as a fellow, he became faculty in the Division of Rheumatology at NYU-Langone Hospital for Joint Diseases.
Over the last several years his research has focused on the role of the human microbiome (the totality of microorganisms and their genes residing in the human body) as determinant of autoimmunity and rheumatic diseases. Mentored by Drs Steven Abramson, Dan Littman, Gerald Weissmann and Marty Blaser, Dr Scher helped establish (and now direct) the Microbiome Center for Rheumatology and Autoimmunity (MiCRA). His investigations have led to the observation of oral and gut microbiome community alterations (dysbiosis) in patients with rheumatoid and psoriatic arthritis. His current research focus is understanding how changes in mucosal microbiome modulate distal inflammatory responses and/or serve as markers for immunomodulation.
Dr Scher receives funding from the NIH and the Arthritis Foundation, has written extensively on the field of microbiome, and has lectured nationally and internationally on the pathogenesis of rheumatoid and psoriatic arthritis.
Mukundan Attur, PhD, is Associate Professor of Medicine in the Department of Medicine, Division of Rheumatology, of NYU School of Medicine, NYU Langone Health, New York, NY, USA. He received his PhD degree from Madurai Kamaraj University, India, and joined the NYU Division of Rheumatology. Dr Attur's interests are in the expression and role of inflammatory mediators in osteoarthritic cartilage, with the aim to elucidate the autocrine and paracrine mechanisms of action of inflammatory cytokines and lipids (eicosanoids) in chondrocytes using genomics and proteomics approaches. Dr Attur is privileged to work under the supervision of Dr Steven B. Abramson, with whom he has developed transcriptome and protein-based biomarkers to identify subjects at risk for development of severe knee osteoarthritis. Currently, as Director of the Rheumatology Research Laboratory at NYU Hospital for Joint Diseases, Dr Attur has established and maintained the arthritis biobank. His current research focuses on the pathophysiology, diagnosis, and treatment of osteoarthritis, with special interest in extracellular non-collagenous proteins expressed in bone and cartilage. Dr Attur, through a proteogenomics-system biology approach, has identified several genes and proteins that are now examined as biomarkers to predict knee osteoarthritis development and progression. He is the author of over 69 publications and numerous invited reviews.